WO2007125226A2 - Peptides modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoïde - Google Patents

Peptides modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoïde Download PDF

Info

Publication number
WO2007125226A2
WO2007125226A2 PCT/FR2007/000758 FR2007000758W WO2007125226A2 WO 2007125226 A2 WO2007125226 A2 WO 2007125226A2 FR 2007000758 W FR2007000758 W FR 2007000758W WO 2007125226 A2 WO2007125226 A2 WO 2007125226A2
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
citrullyl
citrullinated
residue
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/000758
Other languages
English (en)
French (fr)
Other versions
WO2007125226A3 (fr
Inventor
Cyril Clavel
Mireille Sebbag
Maria Leonor Nogueira
Guy Serre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Toulouse
Original Assignee
Universite Toulouse III Paul Sabatier
Universite de Toulouse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Toulouse III Paul Sabatier, Universite de Toulouse filed Critical Universite Toulouse III Paul Sabatier
Priority to JP2009508423A priority Critical patent/JP5377288B2/ja
Priority to US12/299,107 priority patent/US9388226B2/en
Priority to CA2650864A priority patent/CA2650864C/fr
Priority to EP07765933A priority patent/EP2026830B1/fr
Priority to DK07765933.2T priority patent/DK2026830T3/da
Priority to ES07765933T priority patent/ES2392882T3/es
Publication of WO2007125226A2 publication Critical patent/WO2007125226A2/fr
Publication of WO2007125226A3 publication Critical patent/WO2007125226A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This model is particularly suitable for evaluating the modulation properties of the inflammation of a molecule, and in particular its anti-inflammatory properties.
  • said IgG can be further purified by chromatography using a citrullinated antigen such as citrullinated fibrinogen, citrullinated filaggrin, citrullinated vimentin, etc.
  • a citrullinated antigen such as citrullinated fibrinogen, citrullinated filaggrin, citrullinated vimentin, etc.
  • Monoclonal AAPCs, or products produced by genetic recombination, may also be used.
  • the invention further relates to a kit (or kit) for carrying out a process according to the invention, characterized in that it comprises a citrullinated peptide antigen optionally immobilized on a solid support, and citrullinated peptide autoantibodies (AAPC) capable of forming an immune complex with said antigen.
  • a kit for carrying out a process according to the invention, characterized in that it comprises a citrullinated peptide antigen optionally immobilized on a solid support, and citrullinated peptide autoantibodies (AAPC) capable of forming an immune complex with said antigen.
  • AAPC citrullinated peptide autoantibodies
  • SEQ ID NO: 3 wherein X 1 and X 2 are citrullyl residues, or a peptide comprising a fragment of at least 5 consecutive amino acids of said sequence containing said citrullyl residues; a peptide defined by the sequence
  • the present invention thus relates to pharmaceutical compositions, characterized in that they comprise, as active ingredient, at least one citrullinated peptide as defined above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PCT/FR2007/000758 2006-05-03 2007-05-03 Peptides modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoïde Ceased WO2007125226A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2009508423A JP5377288B2 (ja) 2006-05-03 2007-05-03 慢性関節リウマチの治療に有用な、マクロファージの活性を調整するペプチド
US12/299,107 US9388226B2 (en) 2006-05-03 2007-05-03 Peptides modulating the activity of macrophages, useable for the treatment of rheumatoid arthritis
CA2650864A CA2650864C (fr) 2006-05-03 2007-05-03 Peptides modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
EP07765933A EP2026830B1 (fr) 2006-05-03 2007-05-03 Peptides modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoïde
DK07765933.2T DK2026830T3 (da) 2006-05-03 2007-05-03 Peptidmodulatorer for aktiviteten af makrofager, der er egnet til behandling af rheumatoid polyarthritis
ES07765933T ES2392882T3 (es) 2006-05-03 2007-05-03 Péptidos moduladores de la activación de macrófagos, utilizables para el tratamiento de la artritis reumatoide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR06/03956 2006-05-03
FR0603956A FR2900657B1 (fr) 2006-05-03 2006-05-03 Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide

Publications (2)

Publication Number Publication Date
WO2007125226A2 true WO2007125226A2 (fr) 2007-11-08
WO2007125226A3 WO2007125226A3 (fr) 2007-12-27

Family

ID=37401063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/000758 Ceased WO2007125226A2 (fr) 2006-05-03 2007-05-03 Peptides modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoïde

Country Status (8)

Country Link
US (1) US9388226B2 (enExample)
EP (1) EP2026830B1 (enExample)
JP (1) JP5377288B2 (enExample)
CA (1) CA2650864C (enExample)
DK (1) DK2026830T3 (enExample)
ES (1) ES2392882T3 (enExample)
FR (1) FR2900657B1 (enExample)
WO (1) WO2007125226A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2032697A1 (en) * 2006-06-26 2009-03-11 DSMIP Assets B.V. Peptidylarginine deiminase and uses thereof in the production of citrullinated proteins and peptides
JP2011530077A (ja) * 2008-08-04 2011-12-15 シンメッド リサーチ ゲーエムベーハー 組織から循環系に再循環させられる血中マクロファージによって組織から細胞内に吸収される分子マーカーを特徴づける、具体的には定量化する、ための方法
WO2022195239A1 (fr) * 2021-03-19 2022-09-22 Universite Toulouse Iii - Paul Sabatier Cellule immunitaire comprenant un recepteur fc a sa surface, et sur lequel est greffe une molecule hybride comprenant un fragment fc d'anticorps et au moins un peptide citrulline derive de la fibrine, et ses utilisations

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9975944B2 (en) 2013-03-12 2018-05-22 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
FR3108515B1 (fr) * 2020-03-26 2022-03-25 Ct Hospitalier Universitaire Toulouse Colonne d’aphérèse pour le traitement de la polyarthrite rhumatoïde
JPWO2024057793A1 (enExample) * 2022-09-13 2024-03-21

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2155899A (en) * 1997-11-28 1999-06-16 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
FR2773078B1 (fr) * 1997-12-30 2000-05-26 Univ Toulouse Utilisation de peptides citrullines derives de la filaggrine pour le traitement de la polyarthrite rhumatoide
FR2795735B1 (fr) 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
WO2002048180A2 (de) 2000-12-12 2002-06-20 Fibrex Medical Research & Development Gmbh Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels
GB0030309D0 (en) 2000-12-12 2001-01-24 Univ Aberdeen Antibodies,Peptides,Analogs and uses thereof
WO2006048556A1 (fr) * 2004-11-04 2006-05-11 Biomerieux Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyartrhite rhumatoide, et leurs utilisations

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2032697A1 (en) * 2006-06-26 2009-03-11 DSMIP Assets B.V. Peptidylarginine deiminase and uses thereof in the production of citrullinated proteins and peptides
JP2011530077A (ja) * 2008-08-04 2011-12-15 シンメッド リサーチ ゲーエムベーハー 組織から循環系に再循環させられる血中マクロファージによって組織から細胞内に吸収される分子マーカーを特徴づける、具体的には定量化する、ための方法
WO2022195239A1 (fr) * 2021-03-19 2022-09-22 Universite Toulouse Iii - Paul Sabatier Cellule immunitaire comprenant un recepteur fc a sa surface, et sur lequel est greffe une molecule hybride comprenant un fragment fc d'anticorps et au moins un peptide citrulline derive de la fibrine, et ses utilisations
FR3120877A1 (fr) * 2021-03-19 2022-09-23 Universite Toulouse Iii - Paul Sabatier Cellule immunitaire comprenant un récepteur Fc à sa surface, et sur lequel est greffé une molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide citrulliné dérivé de la fibrine, et ses utilisations

Also Published As

Publication number Publication date
JP5377288B2 (ja) 2013-12-25
ES2392882T3 (es) 2012-12-14
DK2026830T3 (da) 2012-10-08
CA2650864A1 (fr) 2007-11-08
US20090298778A1 (en) 2009-12-03
EP2026830B1 (fr) 2012-06-27
US9388226B2 (en) 2016-07-12
EP2026830A2 (fr) 2009-02-25
WO2007125226A3 (fr) 2007-12-27
JP2009536182A (ja) 2009-10-08
FR2900657A1 (fr) 2007-11-09
FR2900657B1 (fr) 2009-04-17
CA2650864C (fr) 2015-02-24

Similar Documents

Publication Publication Date Title
JP4932112B2 (ja) 診断及び治療用エピトープ並びにトランスジェニック植物
KR100704814B1 (ko) 시클릭 보로프롤린 화합물
JP3445917B2 (ja) 抗原特異的活性化ｔ細胞
JP2000512981A (ja) ａＰＬ免疫応答性ペプチド、その結合体およびａＰＬ抗体媒介病理のための処置方法
EP2026830B1 (fr) Peptides modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoïde
RO118758B1 (ro) Peptide cu rol de imunomodulatori, secvenţă de nucleotide, anticorp şi compoziţie farmaceutic
JPH01501939A (ja) 免疫抑制ペプチドおよび使用法
EP0226513A1 (fr) Peptides capables d'inhiber les interactions entre des antigènes et les lymphocytes T4, produits qui en sont dérivés et leurs applications
EP2828285A1 (fr) Inhibiteur de l'hb-egf dérivé du domaine r de la toxine diphtérique pour le traitement des maladies associées a l'activation de la voie hb-egf/egfr
JPH11500719A (ja) インシュリン依存性糖尿病（ｉｄｄｍ）患者に作用する免疫反応および免疫治療分子
EP3294901B1 (en) Autoantigens for diagnosis of rheumatoid arthritis
FR2830940A1 (fr) Procede de selection de ligands d'hla-dp4 et ses applications
EP2376925A1 (fr) Procede d'evaluation de l'immunogenicite des proteines
EP0491014B1 (fr) PEPTIDES DE L'ANTIGENE Sm-D ET LEUR UTILISATION NOTAMMENT POUR LE DIAGNOSTIC DU LUPUS ERYTHEMATEUX DISSEMINE
FR2908134A1 (fr) Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
JP2010235607A (ja) 自己免疫疾患の診断薬と治療薬となるペプチド類
JPH11507620A (ja) 合成ペプチドおよびそれらを含有する医薬組成物
JP2023503630A (ja) 糖尿病患者を階層化する方法
KR0167016B1 (ko) 항원 특이적인 활성화된 t 림프구, 이것의 검출 및 사용방법
CA2289110A1 (fr) Analogues peptidiques et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
FR2798672A1 (fr) Formes acides des peroxyredoxines et leur utilisation comme moyen de diagnostic
EP1438341A1 (fr) Anticorps stimulant la production d'il-1ra
FR2641538A1 (fr) Facteur inhibiteur du complement, sa caracterisation et ses applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07765933

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2650864

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009508423

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007765933

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12299107

Country of ref document: US